BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32581194)

  • 1. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?
    Kazama I
    Drug Discov Ther; 2020 Jul; 14(3):143-144. PubMed ID: 32581194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
    Zhao M
    Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.
    Fatima U; Rizvi SSA; Fatima S; Hassan MI
    J Interferon Cytokine Res; 2020 Oct; 40(10):469-471. PubMed ID: 32881593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
    Loganathan S; Athalye SN; Joshi SR
    Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
    Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
    Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.
    Ayaz S; Crea F
    Epigenomics; 2020 May; 12(10):811-812. PubMed ID: 32495654
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytokine Storm in COVID19: A Neural Hypothesis.
    Ur A; Verma K
    ACS Chem Neurosci; 2020 Jul; 11(13):1868-1870. PubMed ID: 32605374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Inhaled Furosemide a Potential Therapeutic for COVID-19?
    Brennecke A; Villar L; Wang Z; Doyle LM; Meek A; Reed M; Barden C; Weaver DF
    Am J Med Sci; 2020 Sep; 360(3):216-221. PubMed ID: 32622469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological characteristics of chloroquine and suggestions for its use in treatment of coronavirus disease 2019 (COVID-19)].
    Gao Q
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2020 Apr; 32(2):119-122. PubMed ID: 32458599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
    Tang Y; Liu J; Zhang D; Xu Z; Ji J; Wen C
    Front Immunol; 2020; 11():1708. PubMed ID: 32754163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications.
    Pelaia C; Tinello C; Vatrella A; De Sarro G; Pelaia G
    Ther Adv Respir Dis; 2020; 14():1753466620933508. PubMed ID: 32539627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the
    López-Iranzo FJ; López-Rodas AM; Franco L; López-Rodas G
    Curr Pharm Des; 2020; 26(35):4515-4521. PubMed ID: 32787748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.
    Smetana K; Rosel D; BrÁbek J
    In Vivo; 2020; 34(5):3027-3028. PubMed ID: 32871847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
    Javelot H; El-Hage W; Meyer G; Becker G; Michel B; Hingray C
    Br J Clin Pharmacol; 2020 Jun; 86(6):1176-1177. PubMed ID: 32350872
    [No Abstract]   [Full Text] [Related]  

  • 15. The Management of Cytokine Storm in COVID-19.
    Rumende CM; Susanto EC; Sitorus TP
    Acta Med Indones; 2020 Jul; 52(3):306-313. PubMed ID: 33020343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to follow-up a patient who received tocilizumab in severe COVID-19: a case report.
    Podlasin RB; Kowalska JD; Pihowicz A; Wojtycha-Kwaśnica B; Thompson M; Dyda T; Czeszko-Paprocka H; Horban A
    Eur J Med Res; 2020 Aug; 25(1):37. PubMed ID: 32854774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine Storm Drugs Move from CAR T to COVID-19.
    Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
    Dastan F; Abedini A; Shahabi S; Kiani A; Saffaei A; Zare A
    Iran J Allergy Asthma Immunol; 2020 May; 19(S1):10-12. PubMed ID: 32534505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in".
    Castelli V; Cimini A; Ferri C
    Front Immunol; 2020; 11():2132. PubMed ID: 32983172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.
    Benani A; Ben Mkaddem S
    Front Immunol; 2020; 11():1841. PubMed ID: 32793246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.